ABeta

What the laboratory says this test is for

This LC-MS/MS assay measures beta-amyloid 40 (AB40) as well as AB42 in plasma, rather than AB42 alone. This permits the normalization of beta amyloid levels circulating in plasma in different patients. Using the ratio of beta-amyloid 42/beta-amyloid 40, improves sensitivity and specificity for detecting Alzheimer's disease.

What the laboratory says this test is for

Intended use is for Alzheimer's Diagnosis. Independent measurement and interpretation of plasma amyloid ratios (AB42/40) and phosphorylated tau levels (p-tau181 and p-tau217) provide clinically valuable insight into patient risk for development of Alzheimer's disease. However, by combining core AD pathological markers for a single analytical interpretation have been shown to significantly improve predictive performance and accuracy for detecting amyloid positivity and confirming a diagnosis of Alzheimer's disease. The AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma evaluates a patient's plasma AB42/40 ratios and p-tau217 levels reporting out the likelihood that a symptomatic patient suspected of AD has a High, Indeterminant, or Low likelihood of amyloid pathology consistent with AD. This panel meets established performance criteria for confirming a diagnosis of Alzheimer's disease utilizing plasma biomarkers.

What the laboratory says this test is for

This LC-MS/MS assay measures beta-amyloid 40 (AB40) as well as AB42 in cerebrospinal fluid (CSF), rather than AB42 alone. This permits the normalization of beta amyloid levels circulating in CSF in different patients. Using the ratio of beta-amyloid 42/beta-amyloid 40, improves sensitivity and specificity for detecting Alzheimer's disease.